Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.

Hdl Handle:
http://hdl.handle.net/10147/264502
Title:
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.
Authors:
Reeves, Emer P; Molloy, Kevin; Pohl, Kerstin; McElvaney, Noel G
Affiliation:
Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland. emerreeves@rcsi.ie
Citation:
Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. 2012, 2012:465230 ScientificWorldJournal
Journal:
TheScientificWorldJournal
Issue Date:
2012
URI:
http://hdl.handle.net/10147/264502
DOI:
10.1100/2012/465230
PubMed ID:
22645424
Abstract:
The pathogenesis of lung disease in cystic fibrosis is characterised by decreased airway surface liquid volume and subsequent failure of normal mucociliary clearance. Mucus within the cystic fibrosis airways is enriched in negatively charged matrices composed of DNA released from colonizing bacteria or inflammatory cells, as well as F-actin and elevated concentrations of anionic glycosaminoglycans. Therapies acting against airway mucus in cystic fibrosis include aerosolized hypertonic saline. It has been shown that hypertonic saline possesses mucolytic properties and aids mucociliary clearance by restoring the liquid layer lining the airways. However, recent clinical and bench-top studies are beginning to broaden our view on the beneficial effects of hypertonic saline, which now extend to include anti-infective as well as anti-inflammatory properties. This review aims to discuss the described therapeutic benefits of hypertonic saline and specifically to identify novel models of hypertonic saline action independent of airway hydration.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Animals; Anti-Infective Agents; Child; Child, Preschool; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Elasticity; Humans; Infant; Infant, Newborn; Infection; Inflammation; Lung; Lung Diseases; Mucociliary Clearance; Mucus; Mutation; Respiratory System; Saline Solution, Hypertonic
ISSN:
1537-744X

Full metadata record

DC FieldValue Language
dc.contributor.authorReeves, Emer Pen_GB
dc.contributor.authorMolloy, Kevinen_GB
dc.contributor.authorPohl, Kerstinen_GB
dc.contributor.authorMcElvaney, Noel Gen_GB
dc.date.accessioned2013-01-08T15:50:04Z-
dc.date.available2013-01-08T15:50:04Z-
dc.date.issued2012-
dc.identifier.citationHypertonic saline in treatment of pulmonary disease in cystic fibrosis. 2012, 2012:465230 ScientificWorldJournalen_GB
dc.identifier.issn1537-744X-
dc.identifier.pmid22645424-
dc.identifier.doi10.1100/2012/465230-
dc.identifier.urihttp://hdl.handle.net/10147/264502-
dc.description.abstractThe pathogenesis of lung disease in cystic fibrosis is characterised by decreased airway surface liquid volume and subsequent failure of normal mucociliary clearance. Mucus within the cystic fibrosis airways is enriched in negatively charged matrices composed of DNA released from colonizing bacteria or inflammatory cells, as well as F-actin and elevated concentrations of anionic glycosaminoglycans. Therapies acting against airway mucus in cystic fibrosis include aerosolized hypertonic saline. It has been shown that hypertonic saline possesses mucolytic properties and aids mucociliary clearance by restoring the liquid layer lining the airways. However, recent clinical and bench-top studies are beginning to broaden our view on the beneficial effects of hypertonic saline, which now extend to include anti-infective as well as anti-inflammatory properties. This review aims to discuss the described therapeutic benefits of hypertonic saline and specifically to identify novel models of hypertonic saline action independent of airway hydration.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to TheScientificWorldJournalen_GB
dc.subject.meshAdolescent-
dc.subject.meshAnimals-
dc.subject.meshAnti-Infective Agents-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshCystic Fibrosis-
dc.subject.meshCystic Fibrosis Transmembrane Conductance Regulator-
dc.subject.meshElasticity-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshInfant, Newborn-
dc.subject.meshInfection-
dc.subject.meshInflammation-
dc.subject.meshLung-
dc.subject.meshLung Diseases-
dc.subject.meshMucociliary Clearance-
dc.subject.meshMucus-
dc.subject.meshMutation-
dc.subject.meshRespiratory System-
dc.subject.meshSaline Solution, Hypertonic-
dc.titleHypertonic saline in treatment of pulmonary disease in cystic fibrosis.en_GB
dc.typeArticleen
dc.contributor.departmentRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland. emerreeves@rcsi.ieen_GB
dc.identifier.journalTheScientificWorldJournalen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.